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he phrase “location, location, location” has been12
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116Tused in the real estate business for more than 90
years to convey the overriding importance of location in
determining value, function, and opportunity. It now may be
important in how we approach pancreatitis.
Pancreatitis is a painful and often debilitating disease for
which there are no speciﬁc or effective treatments. Although
patient mortality has decreased over the past 40 years, this is
attributed to improvements in supportive care. The reason
why pancreatitis is so difﬁcult to treat likely is owing to
2 interrelated problems. First, the pancreas is unique in its
biology. It is the only organ that produces vast amounts
of digestive enzymes that, if activated in the wrong location
(ie, within the gland itself instead of the duodenum), can
induce a catastrophic process known as autodigestion. Once
pancreatitis has been initiated, global inhibition of numerous
enzymes including proteases, elastase, lipases, and so forth is
a difﬁcult task. However, if that was the only problem,
perhaps a solution could be found. The second problem
complicating pancreatitis treatment is that injury to the
pancreas initiates an inﬂammatory cascade characterized by
release of cytokines and chemokines that induce a systemic
inﬂammatory response. When severe, this cytokine storm
rains down signiﬁcant mortality. Cytokine production within
pancreatic acinar cells follows activation of key inﬂammatory
pathways that immediately follow pancreatic injury.
Together, pancreatic enzyme activation and its associated
autodigestion compounded by a complicated inﬂammatory
reaction pose a daunting therapeutic hurdle.
Daunting, yes, but perhaps not insurmountable. Aside
from preventing pancreatic injury in the ﬁrst place, the most
logical approach to treating pancreatitis is to abrogate the
injury at the most proximal step, before enzyme and cytokine
activation. But where is that step?
Alterations in intracellular calcium handling consistently
accompany pancreatic injury, leading to pancreatitis. This
indicates that precise regulation of the cellular Ca2þ
concentration is critical for pancreatic health. Calcineurin is
a serine/threonine-speciﬁc protein phosphatase that is
activated by Ca2þ and calmodulin. Calcineurin is best known
for its dephosphorylation and activation of the transcription
factor nuclear factor of activated T cell, cytoplasmic (NFATc).
Upon activation in T cells, NFATc is translocated to the
nucleus and up-regulates cytokine expression. However,
calcineurin also is found in pancreatic acinar cells where it
mediates pancreatic protein synthesis1 and trypsin activa-
tion,2 a key enzyme in the generation of other proteolytic
enzymes. Thus, calcineurin by virtue of its effects on NFATc
may be a node in the pathway for both enzyme and cytokine
activation in the pancreas.
To this end, Orabi et al,3 in this issue of Cellular and
Molecular Gastroenterology and Hepatology, evaluated theCe
EDI 5.4.0 DTD  JCMGH176 proof  23role of calcineurin in an animal model of endoscopic retro-
grade cholangiopancreatography (ERCP)-induced pancrea-
titis. This group previously reported that pancreatitis
produced by injection of either bile acids or radiocontrast
into the pancreatic duct activated calcineurin and nuclear
factor-kB and was ameliorated by pharmacologic calcineurin
inhibition or global deletion of the calcineurin gene in mice.4
Although this earlier work showed a critical role for cal-
cineurin in the generation of pancreatitis, it did not clarify the
location of the calcineurin that was involved. Was calcineurin
in T cells or acinar cells important for pancreatitis? To
address this question, Orabi et al3 deleted the calcineurin
gene speciﬁcally in acinar cells in conditional knockout mice
or with an acinar cell–speciﬁc viral targeting vector. Their
results showed that calcineurin in the pancreas mediated
acute pancreatitis. This led to their concluding experiment
showing that injection of the calcineurin inhibitors FK506
or cyclosporine into the pancreatic duct along with
radiocontrast in an ERCP-like fashion prevented pancreatitis.
Previous evaluations of calcineurin inhibitors raised
serious concerns about their potential use in pancreatitis. In
2 different mouse models of acute pancreatitis5 and 1 model
of chronic pancreatitis,6 systemically administered phar-
macologic calcineurin inhibitors exacerbated pancreatitis.
Not to be dissuaded by these negative results, other
investigators focusing on the role of calcineurin in T cells
recently showed that pancreatitis severity was reduced
by cyclosporine in a T-cell–mediated mouse model of
autoimmune pancreatitis.7
These conﬂicting ﬁndings most likely reﬂect effects
on different cell types, but at this juncture it is difﬁcult to
judge whether calcineurin inhibitors could offer a possible
treatment for pancreatitis.
However, we must not forget about location. The real
value of the study by Orabi et al3 was proving that it is
calcineurin in acinar cells that mediates ERCP pancreatitis.
The therapeutic implication is that systemic administration
of calcineurin inhibitors is unnecessary. Instead, it may be
possible to inject a calcineurin inhibitor where it is
needed—directly into the pancreatic duct to prevent ERCP
pancreatitis.
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